Behavioral Rehabilitation Market Research Report and Outlook by 2028

The behavioral rehabilitation sector is anticipated to grow significantly, with projections indicating it will reach US$ 540.84 million by 2028, up from US$ 350.63 million in 2021. This growth represents a compound annual growth rate (CAGR) of 6.4% from 2021 through 2028.

Key players in the pharmaceutical industry are essential for the introduction of innovative products that meet the evolving demands of the global market. A notable example is the approval of Lybalvi (a combination of olanzapine and samidorphan), an atypical antipsychotic developed by Alkermes, Inc., based in Ireland. In May 2021, this medication received FDA approval for the treatment of adults suffering from schizophrenia and bipolar I disorder. Such proactive engagement from global market participants is expected to significantly propel market growth.

The behavioral rehabilitation market is categorized based on treatment modalities, which include drugs, counseling, and therapy services. In 2021, the counseling and therapy services segment dominated the market share and is projected to exhibit the highest CAGR during the forecast period.

Furthermore, the market is segmented according to healthcare settings, which encompass anxiety disorders, mood disorders, substance abuse disorders, personality disorders, and attention deficit disorders. The anxiety disorders segment was the largest contributor to market share in 2021 and is expected to maintain the highest growth rate in the coming years.

In terms of healthcare settings, the behavioral rehabilitation market is divided into outpatient behavioral rehabilitation, inpatient behavioral rehabilitation, and residential behavioral rehabilitation. The outpatient segment held the largest market share in 2021 and is projected to achieve the highest CAGR throughout the forecast period.

To compile the report on the behavioral rehabilitation market, various primary and secondary sources were utilized, including reputable organizations such as the National Institute on Drug Abuse, Nanalyze, and the European Commission.